Table: Nippon Shinyaku 6-MTH group results (IFRS)
Nov 14 (Reuters)-
Nippon Shinyaku Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2025 Sep 30, 2024 Mar 31, 2026
LATEST YEAR-AGO COMPANY
RESULTS RESULT FORECAST
Sales 79.65 79.33 168.00
(+0.4 pct) (+8.2 pct) (+4.8 pct)
Operating 19.58 17.87 33.00
(+9.6 pct) (-14.4 pct) (-6.9 pct)
Pretax 20.03 18.20 33.70
(+10.1 pct) (-13.9 pct) (-6.7 pct)
Net 15.76 16.37 26.30
(-3.7 pct) (+1.2 pct) (-19.2 pct)
EPS Basic 233.88 yen 243.09 yen 390.20 yen
EPS Diluted 233.88 yen 243.07 yen
Ann Div 124.00 yen 124.00 yen
-Q2 Div 62.00 yen 62.00 yen
-Q4 Div 62.00 yen 62.00 yen
NOTE - Nippon Shinyaku Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4516.T
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)